Johnson & Johnson Aktie 943981 / US4781601046
160.24
USD
0.22
USD
0.14%
01:58:57
NDN
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | Ausblick | |||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.81 |
| Vanguard Group, Inc. (Subfiler) | 9.07 |
| SSgA Funds Management, Inc. | 5.47 |
| State Street Corp. | 5.39 |
| Vanguard Total Stock Market ETF | 3.11 |
| BlackRock Fund Advisors | 2.76 |
| Vanguard 500 Index Fund | 2.36 |
| BlackRock Institutional Trust Co. NA | 2.23 |
| Geode Capital Management LLC | 1.87 |
| State Farm Investment Management Corp. | 1.22 |
| Fidelity 500 Index Fund | 1.12 |
| T. Rowe Price Associates, Inc. (Investment Management) | 1.03 |
| Norges Bank (13F) | 1.00 |
| Government Pension Fund - Global (The) | 0.98 |
| Wellington Management Co. LLP | 0.97 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 135'100 | 132'200 | 134'500 | 141'700 | 152'700 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.60 | 0.62 | 0.61 | 0.66 | 0.62 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 46'033 | 45'274 | 51'237 | 60'979 | 55'294 |
| Summe Anlagevermögen | 90'232 | 88'152 | 99'644 | 108'774 | 117'763 |
| Summe Aktiva | 152'954 | 157'728 | 174'894 | 182'018 | 187'378 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 30'480 | 28'681 | 36'366 | 34'751 | 40'959 |
| Summe Fremdkapital | 93'202 | 98'257 | 111'616 | 107'995 | 110'574 |
| Summe Eigenkapital | 59'752 | 59'471 | 63'278 | 74'023 | 76'804 |
| Summe Passiva | 152'954 | 157'728 | 174'894 | 182'018 | 187'378 |
Adresse
| One Johnson & Johnson Plaza, 08933 New Brunswick | |
| Telefon | +1 (732) 524-0400 |
| URL | http://www.jnj.com |
Management
|
A. Eugene Washington
Independent Director |
|
Ahmet Tezel
Global Head-Research & Development |
|
Anne M. Mulcahy
Lead Independent Director |
|
Ashley A. McEvoy
Executive VP & Worldwide Chairman-MedTech |
|
Bernardo Tavares
Chief Information Officer |
|
D. Scott Davis
Independent Director |
|
Darius Adamczyk
Independent Director |
|
Elizabeth Forminard
Executive Vice President & General Counsel |
|
Frederic H. Moll
Chief Development Officer |
|
Hubert Joly
Independent Director |
|
James D. Swanson
Global Chief Information Officer & Executive VP |
|
Jennifer A. Doudna
Independent Director |
|
Jennifer L. Taubert
EVP & Worldwide Chairman-Pharmaceuticals |
|
Jessica Moore
Vice President-Investor Relations |
|
Joanne Waldstreicher
Chief Medical Officer |
|
Joaquin Duato
Chairman & Chief Executive Officer |
|
Jonathan Sheh
Director-Workplace Experience |
|
Joseph J. Wolk
Chief Financial Officer & Executive Vice President |
|
Kathleen M. Widmer
Group Chairman-Consumer North America |
|
Kathryn E. Wengel
Chief Technical Operations & Risk Officer |
|
Lisa Paley
Vice President-US Sales |
|
Lisa Romanko
Senior Director-Investor Relations |
|
Marc Larkins
Secretary |
|
Marillyn A. Hewson
Independent Director |
|
Mark Alan Weinberger
Independent Director |
|
Mark B. McClellan
Independent Director |
|
Mary C. Beckerle
Independent Director |
|
Matthew Stuckley
Senior Finance Director |
|
Meredith Stevens
Vice President |
|
Michael Bzdak
Global Dir-Employee Engagement-Global Cmnty Impact |
|
Nadja Y. West
Independent Director |
|
Neil Ackerman
Head-Innovation, Global Supply & Transformation |
|
Paul Ruh
Chief Financial Officer-Consumer Health |
|
Paula A. Johnson
Independent Director |
|
Peter M. Fasolo
Chief Human Resources Officer & Executive VP |
|
Robert J. Decker
Chief Accounting Officer & Controller |
|
Ronald A. Kapusta
Chief Accounting Officer & Controller |
|
Scott White
Company Group Chairman |
|
Thomas J. Spellman
Secretary |
|
Warren Foust
President-Surgical Vision |
|
William E. Cohn
Vice President-Medical Devices |